For Immediate Release
Chicago, IL – October 17, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Bayer Aktiengesellschaft (OTCMKTS: (OTC:BAYRY) – Free Report), Monsanto Co. (NYSE: (NYSE:MON) – Free Report), Adaptimmune Therapeutics plc (Nasdaq: (NASDAQ:ADAP) – Free Report) and Celgene Corporation (Nasdaq: (NASDAQ:CELG) – Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Monday’s Analyst Blog:
Bayer to Sell Select Business Lines to Close Monsanto Buyout
Bayer Aktiengesellschaft (OTCMKTS: BAYRY – Free Report) has inked a deal to sell selected Crop Science businesses to BASF for EUR 5.9 billion. Notably, the company intends to divest these assets as a part of its strategy to complete the planned acquisition of Monsanto Co. (NYSE: MON – Free Report).
The divestiture is subject to the closure of Monsanto deal and Bayer is working with the relevant authorities to end the acquisition by early next year. In fact, the company plans to utilize the net proceeds from the divestiture for partially refinancing the planned acquisition of Monsanto.
Markedly, the assets to be divested include Bayer’s global glufosinate-ammonium non-selective herbicide business and the related LibertyLink technology for herbicide toleranceas well as its seed businesses for key row crops in select markets. The transaction includes respective research and development capabilities as well. In 2016, revenue from these businesses amounted to around €1.3 billion.
So far this year, Bayer’s shares have outperformed the industry. The stock has rallied 34.1% compared with the industry’s gain of 18.3%.
More than 1,800 commercial, R&D, breeding and production personnel will be transferred from Bayer to BASF.
Meanwhile, Bayer will continue to own, operate and maintain these businesses until the closing of this divestiture.
In Sep 2016, Bayer signed a definitive merger agreement to acquire U.S. seed giant Monsanto Company in a deal worth approximately $66 billion. The combined business is expected to boost Bayer’s Crop Science business and provide accretion to its core earnings from the first full year of the closing of the transaction, followed by double-digit percentage growth.
Bayer also expects annual earnings contributions of around $1.5 billion from synergies after three years of closing the transaction, as well as additional future benefits from integrated offerings. We believe that the proposed Monsanto acquisition is a strategic move which will offer Bayer with a broad set of solutions to meet farmers’ current and future needs.
Zacks Rank & Stocks to Consider
Bayer carries a Zacks Rank #3 (Hold). Some better-ranked stocks in health care sector include Adaptimmune Therapeutics plc (Nasdaq: ADAP – Free Report) and Celgene Corporation (Nasdaq: CELG – Free Report) holding a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Adaptimmune’s loss per share estimates have narrowed from $1.07 to 95 cents for 2017 and from $1 to 90 cents for 2018 over the last 60 days. The company delivered positive earnings surprises in three of the trailing four quarters, with an average beat of 2.56%. The share price of the company has increased 88.6% year to date.
Celgene’s earnings per share estimates have moved up $9 to $9.02 for 2018. The company pulled off positive earnings surprises in all the trailing four quarters, with an average beat of 3.80%. The share price of the company has increased 17.9% year to date.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Get the full Report on BAYRY - FREE
Get the full Report on MON - FREE
Get the full Report on ADAP - FREE
Get the full Report on CELG - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook (NASDAQ:FB): https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
Bayer AG (DE:BAYGN
Celgene Corporation (CELG): Free Stock Analysis Report
Adaptimmune Therapeutics PLC (ADAP): Free Stock Analysis Report
Monsanto Company (MON): Free Stock Analysis Report
Original post
Zacks Investment Research